Imo the solution to get AHZ out of this tight spit is very simple; assuming the break even point is $40m revenue and they continue to grow at 20% Q on Q and flat growth for infusion 2018 fy total will be approximately $28m. At the same growth rate which is is very conservative fy 2019 should total approx $40m. This does not include any additional products, increased growth or additional infusion revenue. So the current figures are not that stark. Anyone could write a business case to attract equity, finance on these figures with a well proven product track record and pipeline. I have written business cases for approval of funds for returns with much less potential and of quantities sonar to what is required to keep AHZ a going concern. Surely our COD can achieve this, it is not a high risk venture if it is presented correctly. This is not as big a problem as it appears and requires some carefully planning and genuine effort.
The best of luck to all
- Forums
- ASX - By Stock
- AVR
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-247
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$9.99 |
Change
-0.910(8.35%) |
Mkt cap ! $211.1M |
Open | High | Low | Value | Volume |
$10.50 | $10.79 | $9.30 | $1.477M | 149.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $9.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.99 | 1999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 9.700 |
2 | 146 | 9.600 |
1 | 1050 | 9.500 |
1 | 1500 | 9.420 |
1 | 1050 | 9.400 |
Price($) | Vol. | No. |
---|---|---|
9.990 | 1999 | 1 |
10.000 | 493 | 1 |
10.300 | 1000 | 1 |
10.450 | 357 | 1 |
10.600 | 11800 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |